3SBio’s Strong Financial Performance and Expanding Pipeline Justify Buy Rating

3SBio (TRSBF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jill Wu from CMB International Securities maintained a Buy rating on the stock and has a HK$14.18 price target.

Jill Wu’s rating is based on several compelling factors. 3SBio has demonstrated a robust financial performance in 2024, with a significant increase in both revenue and net profit, surpassing previous estimates. This growth is largely driven by the strong performance of key products like TPIAO, which has gained a leading market share in China’s thrombocytopenia treatment market.
Additionally, 3SBio is expanding its commercial portfolio through strategic in-house research and development, as well as business development efforts. The company has submitted new drug applications for several novel therapies and has acquired key assets through in-licensing, indicating a promising pipeline. Furthermore, the advancement of their 707 (PD-1/VEGF) therapy in clinical trials suggests potential for global collaboration. These factors, combined with a strong commercial portfolio and an expanding pipeline, position 3SBio for sustainable long-term growth, justifying the Buy rating.